【摘要】 目的 分析rt-PA静脉溶栓治疗急性脑梗死的临床疗效。方法 收集我院2011年5月~2012年8月期间诊治的68例急性脑梗死患者作为研究对象,随机分为试验组(35例)与对照组(33例),对照组患者采用常规抗血小板聚集药物等治疗,试验组实施rt-PA静脉溶栓治疗,对两组患者治疗前后的NIHSS评分和不良反应发生率进行分析对比。结果 研究结果显示,治疗前试验组患者的NIHSS评分为(9.64±2.37)分,对照组为(9.59±2.41)分,两组患者NIHSS评分比较无明显差异(P>0.05),治疗后试验组患者的NIHSS评分为(5.11±1.68)分,对照组为(7.46±1.71)分,两组患者NIHSS评分均显著降低(P<0.05),且试验组患者降低水平明显大于对照组(P<0.05)。同时,试验组中有8例出现不良反应,不良反应发生率为22.86%,对照组中有17例出现不良反应,不良反应发生率为51.52%,试验组不良反应发生率明显低于对照组(P<0.05)。结论 rt-PA静脉溶栓治疗急性脑梗死具有良好的临床疗效。
doi:10.3969/j.issn.1674-9316.2015.04.112
工作单位:165000黑龙江省大兴安岭地区加格达奇市大兴安岭地区人民医院神经内科
Rt - PA Intravenous Thrombolysis Treatment of Acute Cerebral Infarction Curative Effect Observation
LI Xiuli Neurology,Da Hinggan Ling Prefecture people's hospital of Jiagedaqi city in Heilongjiang province,Jiagedaqi 165000,China
【Abstract】
Objective To analyze the rt - PA intravenous thrombolytic therapy of acute cerebral infarction clinical curative effect. Methods To collect data in May 2011 to August 2012 during the diagnosis and treatment of 68 cases of acute cerebral infarction patients as the research object,were randomly divided into experimental group (35 cases) and control group (33 cases),control group were treated by routine antiplatelet aggregation drug therapy,such as experimental group to implement the rt - PA intravenous thrombolysis treatment,before and after treatment in patients with two groups of NIHSS score and the incidence of adverse reactions were analyzed. Results The results showed that the NIHSS score for patients with treatment before experimental (9.64±2.37),the control group is (9.59±2.41) points,two groups of patients with NIHSS score was no significant difference (P > 0.05),treatment group after treatment in patients with NIHSS score of (5.11±1.68 mm),control group is (7.46±1.71)points,NIHSS score of two groups of patients were significantly lower (P < 0.05),and reduce the level of experimental group patients significantly greater than the control group (P < 0.05). At the same time,with 8 cases with adverse reaction in treatment group,the incidence of adverse reactions was 22.86%,adverse reactions,17 cases appear in the control group,the incidence of adverse reactions was 51.52%,treatment group adverse reactions was significantly lower than the control group (P < 0.05). Conclusion rt - PA intravenous thrombolysis treatment of acute cerebral infarction with good clinical efficacy.
【Key words】 rt - PA intravenous thrombolysis,Acute cerebral infarction,Clinical curative effect
1 资料与方法
1.1 一般资料
收集我院的68例发病4小时内急性脑梗死患者,随机分为试验组(35例)与对照组(33例),试验组中男20例,女15例,年龄41~82岁,平均年龄(59.33±15.16)岁;对照组中男19例,女14例,年龄40~80岁,平均年龄(58.32±15.24)岁。两组患者一般资料比较差异不具统计学意义(P>0.05)。
1.2 方法
对照组患者采用常规抗血小板聚集药物、降血压、降血脂等治疗,试验组实施rt-PA静脉溶栓治疗,每日用药剂量为0.9 mg/kg,具体用药方法为:先将总剂量的10%在10分钟内静脉滴注完,然后将剩余的90%在1小时内滴完,24小时后实施头颅CT检查,确保无出血后口服拜阿司匹灵,每日剂量为200 mg,氯吡格雷,每日剂量为75 mg,持续口服10天后根据情况改为单一抗血小板聚集药物治疗,并辅以降脂等治疗 [1]。
2 结果
治疗前试验组患者的NIHSS评分为(9.64±2.37)分,对照组为(9.59±2.41)分,两组患者NIHSS评分比较无明显差异(P>0.05),治疗后试验组患者的NIHSS评分为(5.11±1.68)分,对照组为(7.46±1.71)分,两组患者NIHSS评分均显著降低(P<0.05),且试验组患者降低水平明显大于对照组(P<0.05)。试验组中有8例出现不良反应,包括2例梗死灶边缘少量渗血,4例牙龈出血,1例梗死灶边缘少量渗血和1例少量舌头出血,不良反应发生率为22.86%,对照组中有17例出现不良反应,包括4例梗死灶边缘少量渗血,9例牙龈出血,2例梗死灶边缘少量渗血和2例少量舌头出血,不良反应发生率为51.52%,试验组不良反应发生率明显低于对照组(P<0.05)。
3 讨论
临床研究表明,急性脑梗死包括中心坏死区和其周边的缺血半暗带区,对于患者的抢救,最重要的是挽救半暗带区,以促使该区域脑组织的功能全面恢复。通过给予患者超早期溶栓治疗能有效促进半暗带有效血流恢复,以挽救缺血半暗带,并进一步缩小中心坏死区范围,促使患者的缺损神经功能改善 [2]。国外众多医疗研究报道称,在急性脑梗死患者的治疗中,只要患者符合 rt-PA 溶栓适应证且经济条件许可就应及时应用rt-PA开展溶栓治疗,特别是将溶栓时间窗延长至发病后四小时可有效提高缺血性脑卒中患者的治疗效果和预后 [3-4]。
另一方面,不良反应是急性脑梗死溶栓治疗治疗效果的判定,特别是溶栓后颅内外出血并发症,根据相关统计资料称,溶栓后脑出血性转化发生率为2%~11%,是影响患者治疗效果和预后的重要影响因素。本次研究结果显示,试验组患者NIHSS评分降低水平明显大于对照组(P<0.05),表明了rt-PA静脉溶栓治疗急性脑梗死可有效促进患者神经功能缺损改善,以促进患者病情恢复。同时,试验组不良反应发生率明显低于对照组(P<0.05)。由此表明,rt-PA静脉溶栓治疗急性脑梗死具有良好的临床疗效。